Giuseppe Mazza is the founder of Engitix. Engitix has raised $85M in total funding. Latest round: Series A. Based in London, United Kingdom.
Giuseppe Mazza is the Co-founder and CEO of Engitix Therapeutics, a London-based biotech company he has led since its inception in 2016. He advanced and commercialized his groundbreaking research on a proprietary human extracellular matrix (ECM) drug discovery platform to develop therapies for cancer and fibrosis. Mazza is also a Professor, and Engitix was founded as a UCL spinout to advance this research.
Full founder directory · Investor directory · Company funding database · Fundraising library